News & Views | Published:

An avatar for precision cancer therapy

Nature Biotechnology volume 36, pages 10531055 (2018) | Download Citation

Screening patient-derived tumor cell cultures against a drug library is a promising adjunct to clinical decision-making.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. N. Engl. J. Med. 348, 994–1004 (2003).

  2. 2.

    et al. N. Engl. J. Med. 344, 783–792 (2001).

  3. 3.

    et al. N. Engl. J. Med. 378, 113–125 (2018).

  4. 4.

    et al. JCO Precis. Oncol. 2017, (2017).

  5. 5.

    et al. Cancer Res. 76, 3690–3701 (2016).

  6. 6.

    et al. Nat. Genet. 50, 1399–1411 (2018).

  7. 7.

    et al. Science 359, 920–926 (2018).

  8. 8.

    et al. Nat. Med. 21, 1318–1325 (2015).

  9. 9.

    et al. Cell Rep. 21, 3298–3309 (2017).

  10. 10.

    , & N. Engl. J. Med. 377, 2398–2399 (2017).

  11. 11.

    et al. Cell Rep. 6, 377–387 (2014).

Download references

Author information

Affiliations

  1. Shumei Kato and Razelle Kurzrock are at the Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California, USA.

    • Shumei Kato
    •  & Razelle Kurzrock

Authors

  1. Search for Shumei Kato in:

  2. Search for Razelle Kurzrock in:

Competing interests

R.K. receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols and Guardant, as well as receiving consultant fees from Loxo, X Biotech, NeoMed and Actuate Therapeutics, receiving speaker fees from Roche, and holding an ownership interest in IDbyDNA and Curematch Inc.

Corresponding author

Correspondence to Razelle Kurzrock.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4293

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing